In a new study, researchers have identified a key step in the process that leads to leaky vessels and harmful swelling in eye diseases.
The discovery could lead to improved treatments for diseases such as age-related macular degeneration (AMD) and diabetic retinopathy.
These diseases cause leaky blood vessels to grow in the eyes, leading to harmful swelling and progressive vision loss.
The research was conducted by a team at Uppsala University, Sweden.
Currently available treatments block a molecule called VEGF that contributes to both leaking vessels and the growth of new blood vessels in the eye.
This dual role of VEGF means that these treatments can prevent harmful swelling but cause adverse side effects such as the death of nerve and blood-vessel cells.
In this study, the team explored whether it would be possible to block the effect of VEGF on blood-vessel leakiness only while leaving nerve and blood-vessel cells unharmed.
The team examined step by step how VEGF causes eye leakiness in mice with diseases that mimic age-related macular degeneration and diabetic retinopathy.
The animals were engineered to have mutations in proteins in their eyes that are affected by VEGF.
By studying different mutant mice with eye diseases mimicking human conditions, the team identified exactly how VEGF causes vessels to leak.
They applied fluorescent particles to the bloodstream and used microscopy to find these particles outside the blood vessels, or not, depending on whether the leakiness had been stopped by a mutation.
The experiments showed that the effect of VEGF on leakiness could be distinguished from the effect on new blood-vessel formation.
The findings provide an answer to the questions on how blood vessels leak and show that leakage can be stopped without killing the blood vessels.
Using this insight, the team has begun testing drugs that could selectively block this leak-inducing step in the process.
If this approach is effective, it could lead to new treatments that stop leaking without the harmful side effects of existing drugs.
The lead author of the study is Ross Smith, a postdoctoral fellow at the Department of Immunology, Genetics and Pathology, Uppsala University.
The study is published in eLife.
Copyright © 2020 Knowridge Science Report. All rights reserved.
